Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: To compare the optimal administration period of antimicrobial prophylaxis in patients undergoing transurethral enucleation of the prostate for benign prostatic hyperplasia.
Methods: We carried out a randomized controlled trial to compare the differences in incidence of perioperative genitourinary tract infection between single and multiple (3 days) administrations of cefazolin for transurethral enucleation of the prostate in benign prostatic hyperplasia patients without pyuria or bacteriuria between January 2015 and December 2018.
Results: This multicenter randomized controlled trial included 203 patients who underwent a transurethral enucleation of the prostate procedure. All received antimicrobial prophylaxis, and were randomized into those who received single-dose (n = 101) or multiple-dose (n = 102) therapy. The rate of genitourinary tract infection after transurethral enucleation of the prostate for all patients was 1.5%, whereas that in the single-dose group was 1.0% and in the multiple-dose group was 2.0%, which were not significantly different (P = 1.00).
Conclusions: A single dose of antimicrobial prophylaxis as a prophylactic antibacterial drug is sufficient for patients undergoing transurethral enucleation of the prostate who do not have presurgical pyuria or bacteriuria.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/iju.14181 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Expanding treatments for lower urinary tract symptoms, secondary to benign prostatic enlargement. A capacity and budget impact analysis in four Nordic countries.
Scand J Urol
September 2025
Boston Scientific Corporation, Marlborough, MA, USA.
Objectives: This capacity and budget impact analysis considers implications of offering a more diversified benign prostate enlargement (BPE) surgical care offering from a healthcare payer perspective in Sweden, Denmark, Norway and Finland.
Methods: A cohort simulation model compares 4-year treatment costs and capacity impact, including hospital bed-days and operating time, with Transurethral Resection of the Prostate (TURP), Holmium Laser Enucleation of the Prostate (HoLEP) using MOSES™Technology, photoselective vaporisation of the prostate (PVP) and Rezūm™ Water Vapour Therapy (WVTT). Current treatment choice is compared to a hypothetical scenario, where TURP-proportion is reduced to 50% and volumes of HoLEP, PVP and WVTT are increased.
Aquablation versus HoLEP: Propensity score matching analysis of functional outcomes and ejaculation preservation.
Investig Clin Urol
September 2025
Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Purpose: This study aimed to compare the clinical outcomes of Aquablation and Holmium Laser Enucleation of the Prostate (HoLEP) for the treatment of benign prostatic hyperplasia (BPH), with emphasis on functional improvement, ejaculatory preservation, and perioperative safety.
Materials And Methods: We retrospectively analyzed data from January 2023 to March 2024, excluding patients with follow-up shorter than 3 months. Propensity score matching was performed using age, prostate volume, and preoperative prostate-specific antigen (PSA).
Complications of anatomical endoscopic enucleation of the prostate in real-life practice: What we learnt from the 6,193 patients from the Refinement in Endoscopic Anatomical enucleation of Prostate registry.
Cent European J Urol
May 2025
Department of Urology, Ng Teng Fong General Hospital, National University Health System, Singapore.
Introduction: Anatomical endoscopic enucleation of the prostate (AEEP) is a guideline-recommended treatment for benign prostatic hyperplasia (BPH). We aimed to analyze postoperative complications and outcomes within a large real-world database.
Material And Methods: The Refinement in Endoscopic Anatomical enucleation of Prostate (REAP) registry includes patients who received AEEP for BPH in 8 centers worldwide from January 2020 to January 2022.
Does miniaturisation improve holmium laser enucleation of prostate outcomes? A meta-analysis of comparative studies.
Cent European J Urol
May 2025
Department of Urology, University Hospital Southampton, London, United Kingdom.
Introduction: Holmium laser enucleation of the prostate (HoLEP) is a versatile treatment for benign prostatic hyperplasia (BPH), serving as an alternative to transurethral resection of the prostate (TURP) and open/robotic-assisted prostatectomy. Recent advancements have focused on evaluating the impact of smaller (22-24 Fr) vs larger (26-28 Fr) resectoscope sheaths on procedural outcomes.The aim of this study was to assess and compare the safety, efficiency, and complication rates associated with smaller and larger resectoscope sheaths in HoLEP procedures through a meta-analysis.
View Article and Find Full Text PDFImpact of preoperative fasting duration and prostate mass on postoperative bleeding after transurethral enucleation of the prostate: A risk factor analysis.
J Int Med Res
August 2025
Department of Urology, Peking University First Hospital-MiYun Hospital, China.
ObjectiveThis study explored the impact of preoperative fasting duration on patients who underwent transurethral enucleation of the prostate and analyzed the risk factors for postoperative bleeding.MethodsA retrospective analysis was conducted among 51 patients who underwent transurethral enucleation of the prostate for benign prostatic hyperplasia between December 2021 and March 2024. Baseline and perioperative data were collected.
View Article and Find Full Text PDF